This post was originally published on this site Four in 10 adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations respond to treatment with Zejula (niraparib), according to early results of an ongoing Phase 2 trial. The GALAHAD study (NCT02854436), sponsored by Janssen, is testing 300 mg daily Zejula in patients whose disease worsened after treatment with…
This post was originally published on this site With each new advance in medicine comes ethical dilemmas, from fertility treatments and newborn screening, to vaccinations, gene therapies and euthanasia. But rare diseases and the expensive therapies needed to treat them — particularly in an age of scarce economic resources — almost always entail “tragic choices,”…
This post was originally published on this site Aiming to support the development of CMD-502, a new cell-based therapy that uses donor-derived natural killer T-cells to fight cancer, the Cancer Prevention and Research Institute of Texas (CPRIT) has awarded Cell Medica an $8.7 million grant. In addition to being available “off-the-shelf,” the therapy — being developed in collaboration with the Baylor…
This post was originally published on this site Manipulating astrocytes — a type of cell in the brain — to deliver a protein that favors the survival of neurons can rescue cognitive function, including memory, in a mouse model of Alzheimer’s disease, a study reports. The study, “Conditional BDNF delivery from astrocytes rescues memory deficits,…
This post was originally published on this site Mirvetuximab soravtansine, an investigational antibody-drug conjugate targeting the folate receptor alpha (FRα) protein, was no better than chemotherapy at delaying disease progression or death in ovarian cancer patients included in the FORWARD I Phase 3 trial. The treatment failed to extend survival without disease worsening in the…
This post was originally published on this site An under-the-skin injection of daratumumab is as effective as its intravenous formulation, Darzalex (daratumumab), at reducing tumor burden in multiple myeloma patients, a Phase 3 clinical trial shows. The new formulation also led to similar levels of daratumumab in circulation, meeting the trial’s co-primary goals, according to Genmab, the…
This post was originally published on this site The investigational therapy ATYR1923 for pulmonary sarcoidosis may help decrease lung inflammation by halting the infiltration of immune cells called neutrophils into the lungs, according to a preclinical study in mice. Suzanne Paz, PhD, from the therapy’s developer aTyr Pharma, presented the findings in a poster, titled “ATYR1923…
This post was originally published on this site It’s a pretty well-known fact that having access to a support network is an essential tool for surviving any big life struggle. To have people to talk and relate to is extremely remedying. I’ve always known this and yet, for some reason, I never could bring myself…
This post was originally published on this site Long-term treatment with a combination of NeuVax (nelipepimut-S) and Herceptin (trastuzumab) is safe and extends the time without disease resurgence in women with triple-negative breast cancer, according to final results of a Phase 2b trial. NeuVax, developed by Sellas Life Sciences, is an investigational cancer vaccine that contains small pieces derived…
This post was originally published on this site Abnormal levels of amyloid-beta and tau protein — two hallmarks of Alzheimer’s disease — were detected in the cerebrospinal fluid of older individuals without dementia who were hospitalized for hip fractures, a study shows. These findings suggest that alterations that can cause diminished balance in older people may…
